Events
-
-
-
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
Bacteria-enhanced graphene oxide nanoparticles for triple-action tumour eradication
Modern cancer treatments have evolved beyond traditional chemotherapy to include targeted approaches such as immunotherapy,…
Powerful new tool promises major advances in cancer treatment
New Australian technology is set to transform the way that gastrointestinal cancers are detected and…
“Cytokine factory” implant: triggers immune response in metastatic melanoma, pancreatic and colorectal tumours
A team of researchers from Rice University has developed an implantable “cytokine factory” that safely…
Te Aho o Te Kahu releases Analysis of Cancer Medicine Availability in Aotearoa
Today we are releasing our analysis of cancer medicine availability in New Zealand Aotearoa, Understanding the Gap: an analysis of…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.